Physician profile
Lori Straub
NPI 1477720308
$4,262.88
in general payments reported to CMS, 2019-2025
22 companies · $2,385 in 2025
The $2,385 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $186 · 2023: $31.49 · 2024: $1,660 · 2025: $2,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,056 · Education: $20.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,056.22 |
| Education | $20.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $838.80 | 2023-2025 | Caplyta |
| Abbvie INC. | $520.35 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $463.12 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $296.66 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $271.79 | 2024-2025 | Spravato, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $236.50 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $218.20 | 2025 | Fanapt |
| Alkermes, INC. | $216.85 | 2024-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $206.32 | 2024-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $160.52 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $137.94 | 2024-2025 | Trintellix |
| Axsome Therapeutics, INC. | $134.04 | 2024-2025 | Auvelity |
| Abiomed | $108.13 | 2022 | |
| Ironshore Pharmaceuticals INC. | $106.38 | 2024 | |
| Supernus Pharmaceuticals, INC. | $92.47 | 2024-2025 | Qelbree |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $84.80 | 2025 | Azstarys |
| Tris Pharma INC | $48.94 | 2024 | Dyanavel Xr |
| Bausch Health US, LLC | $38.60 | 2025 | Aplenzin |
| Indivior INC. | $29.17 | 2024 | Perseris |
| Sage Therapeutics, LLC | $20.25 | 2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $19.84 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $13.21 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Straub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.